OLIGONUCLEOTIDE SERVICES
Custom Oligonucleotide Synthesis Services
Raysun Biopharma is developing a project-based oligonucleotide service platform in Vientiane, Laos, covering sequence review, synthesis strategy, modification planning, purification and analytical method development. Each program is evaluated according to molecular design, scale, purity target and documentation requirements.
Our intended scope includes research-stage ASOs, siRNA, miRNA, PMOs, aptamers, CpG oligos and selected modified or conjugated formats. Manufacturing availability and GMP status will be confirmed in line with facility qualification and regulatory readiness.
PROJECT SCOPE
Oligonucleotide Service Scope
Vientiane, Lao PDR
Project Location
B2B Project Review
Technical requirements are assessed before scope is defined.
Detailed Design in Progress
Cleanrooms, utilities and equipment integration
Documentation Review
Specific documentation and availability are confirmed after technical review.
PROJECT SCOPE
Oligonucleotide Service Scope
Raysun evaluates each oligonucleotide program individually. Potential scope may include synthesis strategy, oligonucleotide format selection, analytical planning, backbone and terminal modifications, linkers, labeling and conjugation approaches. Availability is confirmed following technical review.
Sequence review, synthesis-route assessment, purification strategy and project-specific scale-up planning.
ASOs, siRNA, miRNA, PMOs, aptamers, CpG oligos, decoys and selected conjugated formats.
Identity, purity, molecular-mass and impurity-profile strategies defined according to project stage.
Project-specific evaluation of 2′-OMe, 2′-MOE, 2′-F, LNA and other selected nucleotide chemistries.
Selected phosphorylation and modified-backbone configurations considered according to sequence requirements.
Selected amino, thiol, biotin and spacer configurations evaluated for labeling or conjugation workflows.
Azide- and alkyne-functionalized oligonucleotides evaluated for compatible conjugation strategies.
Selected fluorescent labels and dark quenchers incorporated where technically appropriate.
PEG linkers and selected peptide–oligonucleotide conjugation concepts evaluated during project scoping.
Oligonucleotide Quality Planning
| ASSESSMENT AREA | TYPICAL CONSIDERATIONS | PROJECT APPROACH |
|---|---|---|
| Appearance | Visual characteristics | Defined in the agreed specification |
| Identity | Molecular mass and/or sequence confirmation | Method selected during technical review |
| Purity | Chromatographic purity and impurity profile | Project-specific method development |
| Content / Assay | Suitable quantitative determination | Based on material type and project stage |
| Water Content | Moisture assessment where required | Project-specific |
| Counter Ions | Ion-profile assessment where applicable | Project-specific |
| Residual Solvents | Process-related solvent assessment | Risk-based evaluation |
| Elemental Impurities | Elemental analysis where required | Based on project stage |
| Endotoxin / Bioburden | Microbiological assessment where applicable | Based on intended use |
| Stability Support | Testing against agreed quality attributes | Defined in the project protocol |